Search results
Results from the WOW.Com Content Network
IORT is typically a component in the multidisciplinary treatment of locally advanced and recurrent cancer, in combination with external beam radiation, surgery, and chemotherapy. As a growing trend in recent years, IORT can also be used in earlier stage cancers such as prostate and breast cancer .
When breast cancer is surgically excised, it can come back (local recurrence) in the remaining breast or on the chest wall in a small proportion of women. Adjuvant radiotherapy is necessary if breast cancer is treated by removing only the cancerous lump with a rim of surrounding normal tissue, as it reduces the chance of local recurrence.
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
For premium support please call: 800-290-4726 more ways to reach us
Almost 300,000 women are to be offered a drug that could nearly half their chances of developing breast cancer. The post-menopausal women in England who are deemed to have a moderate or high risk ...
Fishel said that she did not undergo surgeries or chemotherapy outside of her radiation treatment, and that she will now start Tamoxifen, a medication that can help reduce breast cancer ...
With doctors who are experts in dermatoscopy, the diagnostic accuracy for melanoma is significantly better than those who do not have any specialized training. [3] Thus, there is considerable improvement in the sensitivity (detection of melanomas) as well as specificity (percentage of non-melanomas correctly diagnosed as benign), compared with naked eye examination.
granted for three indications: HER2-positive breast cancer with prior anti-HER2-based treatment; HER2 low (IHC 1+ or IHC 2+/ISH) breast cancer; and non-small cell lung cancer with an activating HER2 mutation Dupilumab: Regeneron Pharmaceuticals: granted for two indications: eosinophilic esophagitis; and atopic dermatitis: Ivosidenib: Servier ...